Irish
drugmaker Shire said on April 24 its board was willing in principle to recommend to shareholders a sweetened 46 billion - pound ($ 64 billion) acquisition offer from rival Takeda Pharmaceutical.
Takeda Pharmaceutical shares lost almost 5 percent of their value on Friday as investors fretted over the size of any deal the Japanese firm would have to make after London - listed
drugmaker Shire rejected its latest $ 63 bln bid.
London - listed
drugmaker Shire and Japan's Takeda Pharmaceuticals plan to announce a preliminary deal on Wednesday, after the latter sweetened its $ 62 billion acquisition offer, Reuters reports.
In January, Sanofi agreed to acquire Biogen's hemophilia spinoff Bioverativ for $ 11.6 billion, and now the Japanese drugmaker Takeda is bidding for the rare - disease
drugmaker Shire.
Not exact matches
LONDON — Japanese
drugmaker Takeda has reached a tentative agreement to buy Ireland - based
Shire for 46 billion pounds in one of the biggest pharma deals to date.
LONDON, April 16 -
Shire, the London - listed rare diseases specialist that is a potential takeover target for Japan's Takeda Pharmaceutical, is selling its oncology business to unlisted French
drugmaker Servier for $ 2.4 billion.
The deal suggests there is value locked up within
Shire's portfolio - despite a dismal share price performance in the past two years - as its management braces for a possible $ 50 - billion bid battle with Japan's biggest
drugmaker.
Shire was also nearly bought by U.S.
drugmaker AbbVie Inc in 2014, until U.S. tax rule changes caused the deal to fall apart.